Matches in SemOpenAlex for { <https://semopenalex.org/work/W1480595770> ?p ?o ?g. }
- W1480595770 abstract "Ustekinumab (CNTO 1275) and briakinumab (ABT-874) are monoclonal antibodies that target the standard p40 subunit of the cytokines interleukin-12 and interleukin-23 (IL-12/23p40), which are involved in the pathogenesis of Crohn's disease.The objectives of this review were to assess the efficacy and safety of anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.We searched the following databases from inception to 12 September 2016: PubMed, MEDLINE, EMBASE, and the Cochrane Library (CENTRAL). References and conference abstracts were searched to identify additional studies.Randomized controlled trials (RCTs) trials in which monoclonal antibodies against IL-12/23p40 were compared to placebo or another active comparator in patients with active Crohn's disease were included. DATA COLLECTION AND ANALYSIS: Two authors independently screened studies for inclusion and extracted data. Methodological quality was assessed using the Cochrane risk of bias tool. The primary outcome was failure to induce clinical remission, defined as a Crohn's disease activity index (CDAI) of < 150 points. Secondary outcomes included failure to induce clinical improvement, adverse events, serious adverse events, and withdrawals due to adverse events. Clinical improvement was defined as decreases of > 70 or > 100 points in the CDAI from baseline. We calculated the risk ratio (RR) and 95% confidence intervals (95% CI) for each outcome. Data were analyzed on an intention-to-treat basis. The overall quality of the evidence supporting the outcomes was evaluated using the GRADE criteria.Six RCTs (n = 2324 patients) met the inclusion criteria. A low risk of bias was assigned to all studies. The two briakinumab trials were not pooled due to differences in doses and time points for analysis. In both studies there was no statistically significant difference in remission rates. One study (n = 79) compared doses of 1 mg/kg and 3 mg/kg to placebo. In the briakinumab group 70% (44/63) of patients failed to enter clinical remission at 6 or 9 weeks compared to 81% (13/16) of placebo patients (RR 0.86, 95% CI 0.65 to 1.14). Subgroup analysis revealed no significant differences by dose. The other briakinumab study (n = 230) compared intravenous doses of 200 mg, 400 mg and 700 mg with placebo. Eighty-four per cent (154/184) of briakinumab patients failed to enter clinical remission at six weeks compared to 91% (42/46) of placebo patients (RR 0.92, 95% CI 0.83 to 1.03). Subgroup analysis revealed no significant differences by dose. GRADE analyses of the briakinumab studies rated the overall quality of the evidence for the outcome clinical remission as low. Based on the results of these two studies the manufacturers of briakinumab stopped production of this medication. The ustekinumab studies were pooled despite differences in intravenous doses (i.e. 1mg/kg, 3 mg/kg, 4.5 mg/kg, and 6 mg/kg), however the subcutaneous dose group was not included in the analysis, as it was unclear if subcutaneous was equivalent to intravenous dosing. There was a statistically significant difference in remission rates. At week six, 84% (764/914) of ustekinumab patients failed to enter remission compared to 90% (367/406) of placebo patients (RR 0.92, 95% CI 0.88 to 0.96; 3 studies; high-quality evidence). Subgroup analysis showed a statistically significant difference for the 6.0 mg/kg dose group (moderate-quality evidence). There were statistically significant differences in clinical improvement between ustekinumab and placebo-treated patients. In the ustekinumab group, 55% (502/914) of patients failed to improve clinically (i.e. 70-point decline in CDAI score), compared to 71% (287/406) of placebo patients (RR 0.78, 95% CI 0.71 to 0.85; 3 studies). Subgroup analysis revealed significant differences compared to placebo for the 1 mg/kg, 4.5 mg/kg and 6 mg/kg dosage subgroups. Similarly for a 100-point decline in CDAI, 64% (588/914) of patients in the ustekinumab group failed to improve clinically compared to 78% (318/406) of placebo patients (RR 0.82, 95% CI 0.77 to 0.88; 3 studies; high-quality evidence). Subgroup analysis showed a significant difference compared to placebo for the 4.5 mg/kg and 6.0 mg/kg (high-quality evidence) dose groups. There were no statistically significant differences in the incidence of adverse events, serious adverse events or withdrawal due to adverse events. Sixty-two per cent (860/1386) of ustekinumab patients developed at least one adverse event compared to 64% (407/637) of placebo patients (RR 0.97, 95% CI 0.90 to 1.04; 4 studies; high-quality evidence). Five per cent (75/1386) of ustekinumab patients had a serious adverse event compared to 6% (41/637) of placebo patients (RR 0.83, 95% CI 0.58 to 1.20; 4 studies; moderate-quality evidence). The most common adverse events in briakinumab patients were injection site reactions and infections. Infections were the most common adverse event in ustekinumab patients. Worsening of Crohn's disease and serious infections were the most common serious adverse events.High quality evidence suggests that ustekinumab is effective for induction of clinical remission and clinical improvement in patients with moderate to severe Crohn's disease. Moderate to high quality evidence suggests that the optimal dosage of ustekinumab is 6 mg/kg. Briakinumab and ustekinumab appear to be safe. Moderate quality evidence suggests no increased risk of serious adverse events. Future studies are required to determine the long-term efficacy and safety of ustekinumab in patients with moderate to severe Crohn's disease." @default.
- W1480595770 created "2016-06-24" @default.
- W1480595770 creator A5028386079 @default.
- W1480595770 creator A5036883744 @default.
- W1480595770 creator A5054386482 @default.
- W1480595770 creator A5057186834 @default.
- W1480595770 date "2016-11-25" @default.
- W1480595770 modified "2023-10-18" @default.
- W1480595770 title "Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease" @default.
- W1480595770 cites W1510772989 @default.
- W1480595770 cites W1514401063 @default.
- W1480595770 cites W1515981258 @default.
- W1480595770 cites W1661616496 @default.
- W1480595770 cites W1761355724 @default.
- W1480595770 cites W1833973510 @default.
- W1480595770 cites W1883408950 @default.
- W1480595770 cites W1890960558 @default.
- W1480595770 cites W1968893079 @default.
- W1480595770 cites W1976676963 @default.
- W1480595770 cites W1979910355 @default.
- W1480595770 cites W1982535535 @default.
- W1480595770 cites W1989963371 @default.
- W1480595770 cites W1991810959 @default.
- W1480595770 cites W1997475166 @default.
- W1480595770 cites W2004608617 @default.
- W1480595770 cites W2007718183 @default.
- W1480595770 cites W2013592287 @default.
- W1480595770 cites W2018542503 @default.
- W1480595770 cites W2041218413 @default.
- W1480595770 cites W2052762949 @default.
- W1480595770 cites W2055879151 @default.
- W1480595770 cites W2075090387 @default.
- W1480595770 cites W2083000727 @default.
- W1480595770 cites W2085127303 @default.
- W1480595770 cites W2097935815 @default.
- W1480595770 cites W2122247171 @default.
- W1480595770 cites W2126807394 @default.
- W1480595770 cites W2127693350 @default.
- W1480595770 cites W2128090799 @default.
- W1480595770 cites W2131727319 @default.
- W1480595770 cites W2133633410 @default.
- W1480595770 cites W2141541678 @default.
- W1480595770 cites W2141679700 @default.
- W1480595770 cites W2152026434 @default.
- W1480595770 cites W2161015371 @default.
- W1480595770 cites W2162481439 @default.
- W1480595770 cites W2165010366 @default.
- W1480595770 cites W2166360124 @default.
- W1480595770 cites W2167152940 @default.
- W1480595770 cites W2168370388 @default.
- W1480595770 cites W2168505126 @default.
- W1480595770 cites W2171341132 @default.
- W1480595770 cites W2313308264 @default.
- W1480595770 cites W2321453230 @default.
- W1480595770 cites W2323430328 @default.
- W1480595770 cites W2331278657 @default.
- W1480595770 cites W2336434784 @default.
- W1480595770 cites W2342066803 @default.
- W1480595770 cites W2921912769 @default.
- W1480595770 cites W2977488709 @default.
- W1480595770 cites W2977857071 @default.
- W1480595770 cites W4229973829 @default.
- W1480595770 cites W4233817719 @default.
- W1480595770 cites W4244822846 @default.
- W1480595770 cites W4248269869 @default.
- W1480595770 cites W4255263208 @default.
- W1480595770 doi "https://doi.org/10.1002/14651858.cd007572.pub3" @default.
- W1480595770 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6464484" @default.
- W1480595770 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27885650" @default.
- W1480595770 hasPublicationYear "2016" @default.
- W1480595770 type Work @default.
- W1480595770 sameAs 1480595770 @default.
- W1480595770 citedByCount "36" @default.
- W1480595770 countsByYear W14805957702015 @default.
- W1480595770 countsByYear W14805957702016 @default.
- W1480595770 countsByYear W14805957702017 @default.
- W1480595770 countsByYear W14805957702018 @default.
- W1480595770 countsByYear W14805957702019 @default.
- W1480595770 countsByYear W14805957702020 @default.
- W1480595770 countsByYear W14805957702021 @default.
- W1480595770 countsByYear W14805957702022 @default.
- W1480595770 countsByYear W14805957702023 @default.
- W1480595770 crossrefType "journal-article" @default.
- W1480595770 hasAuthorship W1480595770A5028386079 @default.
- W1480595770 hasAuthorship W1480595770A5036883744 @default.
- W1480595770 hasAuthorship W1480595770A5054386482 @default.
- W1480595770 hasAuthorship W1480595770A5057186834 @default.
- W1480595770 hasBestOaLocation W14805957702 @default.
- W1480595770 hasConcept C126322002 @default.
- W1480595770 hasConcept C142724271 @default.
- W1480595770 hasConcept C168563851 @default.
- W1480595770 hasConcept C197934379 @default.
- W1480595770 hasConcept C204787440 @default.
- W1480595770 hasConcept C27081682 @default.
- W1480595770 hasConcept C2778975655 @default.
- W1480595770 hasConcept C2779134260 @default.
- W1480595770 hasConcept C2779280984 @default.
- W1480595770 hasConcept C2780132546 @default.
- W1480595770 hasConcept C44249647 @default.
- W1480595770 hasConcept C535046627 @default.